Sasanlimab with Bacillus Calmette-Guérin for treating high-risk non-muscle invasive bladder cancer

Sasanlimab in combination with Bacillus Calmette-Guérin (BCG) is in clinical development for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). Bladder cancer is when cancerous cells develop in the lining of the bladder. NMIBC is the most common type of bladder cancer and is categorised by risk (low, medium and high). High-risk NMIBC is when cancerous cells are more likely to persist or return after treatment, this means people with this type might require additional treatment and monitoring. Symptoms of NMBIC include but are not limited to blood in urine and urination problems. There remains unmet need in the treatment of high-risk NMIBC as recurrence and progression remains common.